GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medicalsystem Biotechnology Co Ltd (SZSE:300439) » Definitions » Debt-to-Equity

Medicalsystem Biotechnology Co (SZSE:300439) Debt-to-Equity : 0.02 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicalsystem Biotechnology Co Debt-to-Equity?

Medicalsystem Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥47 Mil. Medicalsystem Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥20 Mil. Medicalsystem Biotechnology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥2,795 Mil. Medicalsystem Biotechnology Co's debt to equity for the quarter that ended in Mar. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medicalsystem Biotechnology Co's Debt-to-Equity or its related term are showing as below:

SZSE:300439' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.27   Max: 1.1
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of Medicalsystem Biotechnology Co was 1.10. The lowest was 0.01. And the median was 0.27.

SZSE:300439's Debt-to-Equity is ranked better than
93.26% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs SZSE:300439: 0.02

Medicalsystem Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for Medicalsystem Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicalsystem Biotechnology Co Debt-to-Equity Chart

Medicalsystem Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 0.59 0.21 0.13 0.03

Medicalsystem Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.07 0.06 0.03 0.02

Competitive Comparison of Medicalsystem Biotechnology Co's Debt-to-Equity

For the Diagnostics & Research subindustry, Medicalsystem Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicalsystem Biotechnology Co's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medicalsystem Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medicalsystem Biotechnology Co's Debt-to-Equity falls into.



Medicalsystem Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medicalsystem Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Medicalsystem Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicalsystem Biotechnology Co  (SZSE:300439) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Medicalsystem Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medicalsystem Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicalsystem Biotechnology Co (SZSE:300439) Business Description

Traded in Other Exchanges
N/A
Address
No. 299 Qiming South Road, Yinzhou District, Zhejiang Province, Ningbo City, CHN, 315104
Medicalsystem Biotechnology Co Ltd is engaged in research and development, manufacture and distribution of diagnostic products. It provides in-vitro biochemical diagnostic reagents to healthcare facilities.
Executives
Zou Bing De Director
Xiong Hui Ping Secretary Dong
Zhuo Hong Ye Director
Wu Li Shan Supervisors
Fang Liang Executives
Zou Ji Hua Directors, executives
Wo Yan Bo Executives

Medicalsystem Biotechnology Co (SZSE:300439) Headlines

No Headlines